课题基金 / 基金详情

IMPAIRED HEPATIC FUNCTION ON PKS OF PIOGLITAZONE

IMPAIRED HEPATIC FUNCTION ON PKS OF PIOGLITAZONE
吡格列酮 PKS 导致肝功能受损
批准号：
6281022
负责人：
STEVEN SCHENKER
金额：
$1.49万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281022
关键词：
clinical research clinical trial phase I diabetes mellitus therapy human subject hypoglycemic agents liver disorder liver function noninsulin dependent diabetes mellitus pharmacokinetics

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pioglitazone, a drug being developed for the treatment for non-insulin dependent diabetes, improves hyperglycemia by activating the post-receptor phase of the insulin receptor. After oral administration, pioglitazone is concentrated in the liver where it is metabolized; this study is designed to evaluate the effect impaired hepatic function has on the pharmacokinetics of pioglitazone in urine and serum. The study will evaluate changes in the pharmacokinetics of pioglitazone in subjects with known hepatic impairment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
海外基金